GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
This global study is testing different new and standard treatments for glioblastoma, which is a fast-growing and aggressive type of brain tumor. The goal is to quickly find out which treatments work best so patients can get more effective care sooner.
Adults who are 18 or older with a confirmed diagnosis of glioblastoma may be able to join. You must be well enough to handle daily activities and have tissue samples available from a previous surgery or biopsy.
Participants will receive either standard treatments or newer experimental medications designed to fight the brain tumor. Your health care team will closely monitor your progress with regular check-ups and brain scans.
This study is currently recruiting patients at medical centers in locations such as Birmingham, Alabama, and La Jolla and Los Angeles, California. More locations may be available.
- 1Tests multiple different treatments for a serious brain tumor called glioblastoma.
- 2Open to adults aged 18 and older who meet specific health and diagnosis requirements.
- 3Currently recruiting participants at select medical centers in the United States.
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.